Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Draft Guidance Paves Way For Collecting Clinical Study Data Via Digital Health Technologies

Executive Summary

The US FDA released draft guidance on how device makers, investigators and other stakeholders can use digital health solutions to collect data from clinical study participants remotely. Comments are due to the agency by 22 March 2022.

You may also be interested in...



Bayer’s Koenen: Decentralized Trials For Pivotal Studies Not 'Black Or White Scenario'

A cross-section of biopharma experts, including senior executives from Bayer, Boehringer Ingelheim and Accenture, and US FDA Director at the India Office deliberate digitization and evolving trends in clinical research, including the potential of decentralized trials and metadata-driven automation.

Bayer’s Koenen: Decentralized Trials For Pivotal Studies Not 'Black Or White Scenario'

A cross-section of biopharma experts including senior executives of Bayer, Boehringer Ingelheim and Accenture and US FDA Director at the India Office deliberate digitization and evolving trends in clinical research, including the potential of decentralized trials and metadata-driven automation.

Considerations For Using Established Versus Novel Endpoints In Decentralized Trials

UK and US regulators explained why some established clinical endpoints are not suitable for use in decentralized trials, and discussed principles to guide the development of novel digital endpoints.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT144878

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel